Celecoxib may be a viable treatment option for breast cancer patients not treated with chemotherapy.

Based on the P -values calculated from the confidence interval ( 4 ), this estimate barely missed statistical significance by a two-tailed test ( P = 0.07) but did reach statistical significance by a one-tailed test ( P = 0.035), which is the more important test since the trial was designed “to determine whether adjuvant celecoxib could improve disease outcomes among women with early breast cancer”.

also in 44 other papers